Fusion protein · Agonist of OX40 (TNFRSF4) and PD-1 (PDCD1) · developed by Shattuck Labs
SL-279252 is an agonist redirected checkpoint fusion protein built from the extracellular domains of PD-1 and OX40 ligand joined by an Fc domain. It binds PD-1 and OX40 on T-lymphocytes at the same time, aiming to stimulate OX40 while blocking PD-1 signaling. It is being studied in several solid tumors and lymphomas.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03894618 | Phase 1 | Squamous Cell Carcinoma of the Head and Neck | Completed | STTK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diffuse Large B Cell LymphomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaHodgkin LymphomaMelanomaMismatch Repair Deficient or MSI-High Solid TumorsNon Small Cell Lung CancerRenal Cell CarcinomaSquamous Cell Carcinoma of the AnusSquamous Cell Carcinoma of the CervixSquamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma of the SkinUrothelial Carcinoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the STTK page.
See STTK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
STTK catalysts and pipeline →